8-K: Accelerate Diagnostics Files for Chapter 11, Agrees to Asset Sale Terms with Indaba Capital

Accelerate Diagnostics has voluntarily initiated Chapter 11 proceedings and agreed to terms with Indaba Capital Management for the sale of substantially all of its assets.

Summary

• Accelerate Diagnostics, Inc. and its subsidiary filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code on May 8, 2025.
• The company will operate as debtors-in-possession under the jurisdiction of the Bankruptcy Court.
• Accelerate Diagnostics has entered into a term sheet with Indaba Capital Management, L.P. for Indaba to acquire substantially all of the company's assets.
• The aggregate consideration includes a credit bid of $36.9 million and the assumption of certain liabilities.
• The transaction will be implemented under Section 363 of the Bankruptcy Code, subject to court approval and bidding procedures.
• The company has also entered into a DIP Term Sheet with Indaba for a senior secured superpriority postpetition term loan financing facility of up to $12.5 million.
• The DIP Facility will be used to pay costs related to the bankruptcy cases and to fund working capital needs.
• The company cautions that trading in its common stock during the Chapter 11 Cases is highly speculative and poses substantial risks, expecting a significant or complete loss on investment for shareholders.

Sentiment

Score: 2

Explanation: The document indicates significant financial distress, leading to Chapter 11 filing and expected losses for shareholders. The sentiment is negative due to the company's financial situation and the anticipated impact on stakeholders.

Positives

• A DIP financing facility of up to $12.5 million has been committed by Indaba to fund operations during the Chapter 11 process.
• The company has engaged advisors to assist with strategic options, including the sale of assets.

Negatives

• Accelerate Diagnostics filed for Chapter 11 bankruptcy on May 8, 2025.
• The company expects that holders of its common stock will experience a significant or complete loss on their investment.
• The filing of the Bankruptcy Petitions constitutes an event of default that accelerated the company's obligations under its debt instruments.

Risks

• Trading in the company's common stock during the Chapter 11 Cases is highly speculative and poses substantial risks.
• The outcome and timing of the Cases and any potential asset sale are uncertain.
• There are risks associated with the potential adverse impact of the Cases on the company's liquidity and results of operations.
• Uncertainty exists regarding obtaining Court approval of a sale of the company's assets or other conditions to the potential asset sale.

Future Outlook

The company plans to sell its assets pursuant to chapter 11 of the Bankruptcy Code and obtain DIP financing to continue operations during the Cases. The company believes the 363 sale process will be in the best interest of the Company and its stakeholders.

Industry Context

This announcement reflects financial distress within the diagnostics industry, potentially due to factors such as evolving market dynamics, reimbursement pressures, or company-specific challenges in commercializing its products.

Comparison to Industry Standards

• It is difficult to compare Accelerate Diagnostics' situation directly to industry standards without specific financial details and performance metrics relative to its peers.
• However, similar situations have occurred with other companies in the diagnostics space facing financial difficulties, such as Theranos, which faced significant legal and financial challenges due to issues with its technology and business practices.
• Unlike Accelerate Diagnostics, Theranos did not file for bankruptcy but rather dissolved.
• Other companies in the diagnostics space, such as Roche and Abbott, are significantly larger and more diversified, making direct comparisons challenging.

Legal Proceedings

• The company has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware.

Related Party Transactions

• The company has entered into a term sheet with Indaba Capital Management, L.P., a majority holder of the company's prepetition secured notes, for the acquisition of substantially all of the company's assets.

Stakeholder Impact

• Holders of the company's common stock are expected to experience a significant or complete loss on their investment.
• The DIP financing is expected to provide Accelerate with the necessary liquidity to operate in the normal course and meet obligations to its employees, vendors and customers throughout the Chapter 11 proceeding while executing on the sale process.

Next Steps

• The company will seek Bankruptcy Court approval for the DIP financing and the sale process.
• Notice of the proposed sale to Indaba will be given to third parties, and competing bids will be solicited.
• The company will manage the bidding process and evaluate any bids received, in consultation with its advisors and as overseen by the Bankruptcy Court.

Key Dates

Keywords

Chapter 11, bankruptcy, Indaba Capital, asset sale, DIP financing, restructuring, Accelerate Diagnostics